Trump Administration Reverses Kratom Ban After Industry Lobbying, Raising Safety Concerns

The Trump administration has reversed its proposed ban on kratom, an herbal supplement with opioid-like effects, following intense lobbying from the kratom industry. Health officials will now permit certain levels of the substance in products marketed as natural, a significant shift from earlier plans to classify kratom as a Schedule I drug. The decision comes amid growing public debate over kratom's safety and potential for addiction, with proponents citing its use for pain relief and opioid withdrawal, while critics warn of health risks and deaths linked to its use. The reversal could benefit a major Republican donor who faces wrongful death lawsuits connected to kratom products, raising questions about political influence on public health policy. As the FDA and DEA continue to evaluate kratom's risks, this move may complicate efforts to regulate a substance that has been associated with dozens of fatalities. The administration's decision highlights the tension between industry interests and consumer safety in the rapidly expanding supplement market. For now, kratom remains widely available, but the long-term regulatory outlook remains uncertain.